Media ReleasesImugene Limited

View All Imugene Limited News


Imugene, Investor Presentation

HARNESSING B-CELLS FOR CANCER IMMUNOTHERAPY

Investment Highlights

• Novel immuno-oncology B-cell peptide vaccine technology

• Outstanding scientific provenance from leading U.S. and European universities

• Drug is safe and well tolerated

• Sound cash position

• Robust intellectual property portfolio & long patent life including checkpoint inhibitor combinations

• Manufacturing straightforward with low cost of goods

• Published in leading peer review journals


To view Presentation please download PDF attached:
Download this document